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Abstract  
Protein arginine methyltransferase 5 
(PRMT5) regulates gene expression either 
transcriptionallyly by symmetric dimethylation 
of arginine residues on histones H4R3, H3R8 
and H2AR3, or at the post-translational level 
by methylation of non-histone target proteins. 
While emerging evidence suggests that 
PRMT5 functions as an oncogene, its role in 
metabolic diseases is not well defined. We 
investigated the role of PRMT5 in promoting 
high fat-induced hepatic steatosis. High fat diet 
up-regulated PRMT5 levels in the liver, but 
not in other metabolically relevant tissues such 
as skeletal muscle or white and brown adipose 
tissue.  This was associated with repression of 
master transcription regulators involved in 
mitochondrial biogenesis. In contrast, lentiviral 
shRNA-mediated reduction of PRMT5 
significantly decreased PI3K/AKT signaling in  
mouse AML12 liver cells. PRMT5 knockdown 
or knockout decreased basal AKT 
phosphorylation, but boosted the expression of 
PPARα and PGC-1α with a concomitant 
increase of mitochondrial biogenesis. 
Moreover, by overexpressing an exogenous 
wild-type or enzyme-dead mutant PRMT5, or 
by inhibiting PRMT5 enzymatic activity with a 
small molecule inhibitor, we demonstrated that 
the enzymatic activity of PRMT5 is required 
for regulation of PPARα and PGC-1α 
expression and mitochondrial biogenesis. Our 
results suggest that targeting PRMT5 may have 
therapeutic potential for treatment of fatty liver. 
 
Introduction 
The phenotypic spectrum of non-
alcoholic fatty liver disease (NAFLD) is broad 
and may range from simple steatosis to 
steatohepatitis, advanced fibrosis and cirrhosis. 
NAFLD is commonly associated with Type 2 
diabetes, visceral obesity and hyperlipidemia (1). 
There is evidence that increased delivery of non-
esterified fatty acid (NEFA) to the liver [mainly 
from white adipose tissue (WAT)] is 
fundamental to the development of NAFLD 
(2,3). The role of diet in the pathogenesis of 
NAFLD has been investigated both in humans 
and in animal models (4-6). Subjects on a high-
fat diet develop fatty liver (5,6); those on a low-
fat/high-carbohydrate diet develop fatty liver via 
increased de novo fatty acid synthesis (4). In 
addition, high dietary fat intake is associated 
with obesity and insulin resistance. As a 
consequence of insulin resistance, suppression 
of lipolysis by insulin is impaired, leading to 
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increased NEFA delivery to the liver (7,8). Thus 
high dietary fatty acids have profound effects on 
insulin resistance, NAFLD and cardiovascular 
disease (9).  
Phosphatidylinositol-3 kinase (PI3K), a 
lipid kinase, generates the second messenger 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) 
(10). The accumulation of PIP3 recruits protein 
kinase B (AKT) to the cell membrane where it is 
phosphorylated and activated by  
phosphoinositide dependent kinase (PDK) 1 and 
2 (11,12). Downstream of this PI3K/AKT 
pathway is the mammalian target of rapamycin 
(mTOR), a major effector that is specifically 
implicated in the regulation of cell growth via 
nutrient availability and cellular bioenergetics 
(13). Activation of the PI3K-AKT-mTOR 
pathway is accompanied by aberrant lipid 
metabolism in cancers (14), where it increases 
protein levels of sterol regulatory element-
binding proteins (SREBP), and its target, fatty 
acid synthase (FASN) (15,16). Inhibition of the 
mTOR pathway is associated with impaired 
induction of transcription factors, i.e. 
peroxisome proliferator activated receptor-α 
(PPARα) and its target genes, such as carnitine 
palmitoyltransferase 1 (CPT1). Under conditions 
favoring re-esterification over β-oxidation in the 
liver, newly synthesized triglycerides are carried 
on very low density lipoproteins (VLDL) to be 
redistributed to WAT for storage, or to skeletal 
muscle for utilization (under exercise 
conditions). Inhibition of PI3K/AKT can abolish 
insulin-induced suppression of VLDL assembly 
and secretion by regulating the degradation of 
Apolipoprotein B (ApoB) and the gene 
expression of hepatic microsomal triglyceride 
transfer protein (MTTP) (17). Thus, the 
PI3K/AKT/mTOR signaling pathway plays an 
integral role in regulating several pathways 
contributing to lipid homeostasis in the liver, 
including de novo lipid biosynthesis, fatty acid 
β-oxidation (18,19), and VLDL assembly and 
secretion.  
The protein arginine methyltransferase 
family consists of three subfamilies that differ in 
their ability to carry out mono- or asymmetric 
di-methylation (type I), mono- or symmetric di-
methylation (type II), or exclusively 
monomethylation (type III) (20,21). PRMT5 
functions as the major type II arginine 
methyltransferase that symmetrically di-
methylates arginine residues on histones as well 
as non-histone proteins including RNA splicing 
factors and cell cycle regulators (22,23). The 
PRMT5 mediated methylation of histones 
H2AR3 (24), H4R3 (25), and H3R8 (26) 
regulates chromatin structure and influences 
transcription. We have shown that PRMT5 is 
required for activation of adipogenic gene 
expression by promoting adipogenic master 
transcriptional factor PPARγ2 expression during 
pre-adipocyte differentiation (27,28). PRMT5 
has been shown to methylate SREBP1a on R321 
and increases SREBP1a transcriptional activity, 
thereby promoting de novo lipogenesis and 
tumor growth(29). Overexpressing exogenous  
GFP-PRMT5 resulted in elevated levels of 
phospho-AKT in 293T cells(30). However, little 
is known about the role of endogenous PRMT5 
in regulating lipid homeostasis in the context of 
NAFLD.  
In this study, we investigated the 
function of PRMT5 in a diet-induced obesity 
mouse model. We found that high-fat diet 
increased PRMT5 expression in the liver but not 
in other metabolically relevant tissues. Hepatic 
PRMT5 expression, however, was not altered in 
the liver of the obese Agouti mouse, suggesting 
that high-fat diet consumption, but not obesity 
per se, induced PRMT5 expression. Global 
signaling pathway analysis showed that 
knockdown of PRMT5 attenuated PI3K/AKT 
signaling. In the non-transformed mouse liver 
cell line model alpha mouse liver 12 (AML12), 
reducing PRMT5 levels by shRNA or inhibiting 
its enzymatic activity with a small molecule 
inhibitor led to an increase in PPARα and PGC-
1α levels and mitochondrial biogenesis. Our 
results suggest that inhibiting PRMT5 favors β-
oxidation which would contribute to the reversal 
of hepatic steatosis. 
 
Results 
PRMT5 is ubiquitously expressed in mice 
While PRMT5 is ubiquitously expressed 
at varying levels in all mouse tissues examined, 
its expression is most abundant in the spleen and 
kidney and it is expressed in tissues important 
for metabolic control such as liver, muscle, 
brown adipose tissue (BAT) and inguinal white 
adipose tissue (iWAT) (Figure 1A). Similarly, 
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PRMT5 was detected in the cytoplasm as well as 
in the nucleus of the non-transformed 
AML12 murine hepatocyte cell line (Figure 1B).  
 
High-fat diet increases hepatic PRMT5 
expression 
PRMT5 mRNA and protein levels were 
significantly increased in the livers of mice fed a 
high-fat diet (HFD) compared to those fed a 
normal diet (RD), as assessed by Western blot 
analysis (Figure 2A), quantitative PCR (Figure 
2B) and immunofluorescent staining of liver 
sections (Figure 2C). In contrast, high-fat diet 
did not modify PRMT5 expression in other 
metabolic relevant tissues such as muscle, brown 
and inguinal white adipose tissue (Figure 2D). 
To further elucidate the role of PRMT5 in 
hepatic steatosis, we asked if PRMT5 up-
regulation in hepatocytes was associated with 
obesity by examining PRMT5 levels in the liver 
of Agouti mice. Yellow Agouti mice with 
dominant mutations at the Agouti locus develop 
obesity, hyperinsulinemia, insulin resistance, 
hyperglycemia, hyperleptinemia and hepatic 
steatosis in adulthood (31-33). Young Agouti 
mice are lean, but adult animals are obese even 
when they are fed on regular chow (32). 
Therefore, the obesity in adult Agouti mice is 
independent of high fat diet. Unlike the diet 
induced obesity model, PRMT5 protein levels 
were not different in the liver of obese 5-month 
versus normal weight 1-month old Agouti mice 
(Figure 2E). This suggested that the increase of 
PRMT5 was not associated with obesity per se 
but with high-fat diet-induced obesity. 
 
PRMT5 gene silencing decreases PI3K/AKT 
signaling 
We sought to dissect the molecular 
mechanism underlying the regulation of hepatic 
lipid homeostasis by PRMT5. Because PRMT5 
is overexpressed in many cancer cell lines 
(29,34-36), we generated PRMT5 knockdown in 
the non-transformed mouse liver cell line 
AML12 to avoid confounding metabolic effects 
of cancer-related factors in transformed cell 
lines. As shown in Figure 3A, reduction of 
PRMT5 expression was achieved by shRNA 
mediated gene silencing. A global signaling 
network analysis measuring 70 key proteins 
involved in more than 20 signaling pathways 
showed that PRMT5 knockdown decreased the 
PI3K/AKT pathway (Figure 3B). The reduction 
of phospho-AKT Ser473 was detected in the 
array (Supplemental Figure 1), which was 
confirmed by Western blot analysis that also 
showed decreased Thr308 phosphorylation on 
AKT in PRMT5 knockdown cells (Figure 3C). 
To confirm this finding, we utilized the 
inducible PRMT5 knockout mouse embryonic 
fibroblast (MEF) cell line which harbors an ER-
Cre directed PRMT5flox/flox allele (37). When 
treated with 4-hydroxytamoxifen (4-OHT), the 
Cre recombinase translocates to the nucleus and 
excises an exon of PRMT5 to disrupt its 
expression. The PRMT5flox/flox MEF cells were 
cultured in the presence of 2 µM 4-OHT for 10 
days followed by DMEM for 3 days without 4-
OHT. The efficiency of PRMT5 knockout was 
confirmed by Western blot analysis (Figure 3D). 
In this PRMT5 knockout model, complete loss 
of PRMT5 led to a decrease in phospho-AKT 
Thr308 and Ser473. In contrast, up-regulation of 
phospho-AKT Ser473 and Thr308 were detected 
in the liver of mice fed a high-fat diet (Figure 
3E).  
 
PRMT5 regulates the expression of master 
transcription factors of mitochondrial 
biogenesis 
Peroxisome proliferator-activated 
receptor alpha (PPARα) has a central role in 
fatty acid β-oxidation, lipid and lipoprotein 
metabolism, inflammatory response, and 
oxidative stress in the liver. Activation of 
PPARα induces the expression of mitochondrial 
genes in the oxidation pathways (38). 
Peroxisome proliferator-activated receptor 
gamma, coactivator 1 alpha (PGC-1α) is a 
transcriptional co-activator that regulates the 
expression of genes involved in energy 
metabolism. It is the master regulator of 
mitochondrial biogenesis (39-41). We surveyed 
the expression of these transcription factors in 
PRMT5 knockdown cells. Silencing PRMT5 
significantly increased the expression of PPARα 
and PGC-1α (Figure 4 A and B). These results 
were confirmed in PRMT5 knockout MEF cells 
(Figure 4C). Consistent with increased 
expression of PPARα and PGC-1α, the 
expression of mitochondrial biogenesis genes 
such as CytoC and Cox7a-1 was elevated in 
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PRMT5 knockdown cells (Figure 4D). These 
results were replicated in PRMT5 knockout 
MEF cells where the expression of these genes 
were up-regulated (Figure 4E) and 
mitochondrial staining was significantly 
increased (Figure 4F). Activation of PI3K/AKT 
signaling has been shown to induce the 
expression of SREBP1(42,43). Liu et al showed 
that in the liver cancer cell line HepG2, silencing 
PRMT5 decreased SREBP1a translation, but not 
transcription (29). We examined in the PRMT5 
knockdown cells the expression of acetyl-coA 
carboxylase (ACC) and fatty acid synthase 
(FASN), the direct downstream targets of 
SREBP1 in de novo fatty acid synthesis. The 
levels of these proteins were not affected upon 
silencing PRMT5 (Supplemental Figure 2), 
which suggested that the de novo fatty acid 
synthesis is not perturbed by PRMT5 silencing. 
It has been shown that insulin regulates lipid 
deposition in goose liver by activating 
PI3K/AKT/mTOR signaling which suppresses 
VLDL assembly and secretion (44). 
VLDL assembly involves transfer of lipid by the 
microsomal triglyceride transfer protein (MTP) 
to ApoB and fusion of ApoB-containing 
precursor particles with triglyceride droplets to 
form mature VLDL (45). Although PRMT5 
knockdown in mouse liver cells reduced 
PI3K/AKT signaling, it did not affect phospho-
mTOR, or ApoB and MTP gene expression 
(Supplemental Figure 2). In contrast, in PRMT5 
knockout MEF cells, the loss of PRMT5 
significantly decreased the levels of phospho-
AKT, but also had no effect on the expression of 
phospho-mTOR (Supplemental Figure 3).  
 
PRMT5 enzymatic activity is required for the 
regulation of PGC-1α and PPARα expression 
Next, we asked if the enzymatic activity 
of PRMT5 is required for its regulation of PGC-
1α and PPARα expression. To address this 
question, a wild type PRMT5 or a catalytically-
dead PRMT5 (G367A, R368A) double mutant 
(46) was introduced to AML12 cells by transient 
transfection (Figure 5A). As opposed to the 
enzyme-dead mutant, the expression of 
exogenous wild-type PRMT5 elevated phospho-
AKT Thr308 and Ser473 and markedly reduced 
PPARα (Figure 5B). EPZ015666 (GSK3235025) 
is a potent and selective small molecule inhibitor 
targeting the enzymatic activity of PRMT5 with 
a half-maximal inhibitory concentration (IC50) 
of 22 nM in biochemical assays (47). Although 
EPZ015666 decreases cell proliferation in 
various cancer lines (48,49), it did not inhibit 
proliferation in AML12 cells even in the 
presence of high dose EPZ015666 for 8 weeks 
(Supplemental Figure 4). On the contrary, 
EPZ015666 treatment markedly decreased 
phospho-AKT Thr308 and Ser473, but increased 
PPARα in a dose-dependent manner (Figure 5C). 
The expression of PPARα and PGC-1α, the 
master regulators of mitochondrial biogenesis, 
was elevated in the presence of EPZ015666 in a 
dose-dependent manner (Figure 5D) with 
concomitant increased density in mitochondrial 
staining (Figure 5E). Inhibition of PRMT5 
enzymatic activity did not change the phosphor-
mTOR levels in AML12 cells (Supplemental 
Figure 5). As a biological consequence of  
increasing mitochondrial biogenesis and 
promoting fatty acid β-oxidation, lipid 
accumulation in cells treated with PRMT5 
inhibitor was significantly reduced (Figure 5F). 
Collectively, these results suggest that the 
enzymatic activity of PRMT5 is required to 
execute its function in metabolic pathways.  
 
PRMT5 regulates PGC-1α and PPARα 
through phospho-AKT signaling 
We sought to dissect whether PRMT5 directly 
regulates the expression of PPARα and PGC-1α  
or indirectly mediates this through phospho-
AKT signaling.  By analyzing the published 
PRMT5 ChIP-seq data (GEO: GSE75739)(50), 
we failed to identify significant PRMT5 binding 
above the IgG control at these gene loci 
(Supplemental Figure 6). Introducing an 
exogenous activated AKT (Myr-AKT) to 
PRMT5 wild type or knockout cells attenuated 
the increased expression of PPARα and PGC-1α 
due to the loss of PRMT5 (Figure 6A). This 
observation was confirmed in AML 12 
hepatocytes, where the up-regulation of PPARα 
and PGC-1α in PRMT5 knockdown cells was 
blocked by the overexpression of Myr-AKT 
(Figure 6B). These results sugguested that the 
regulation of PPARα and PGC-1α by PRMT5 
was mediated through phospho-AKT signaling, 
although we could not completely rule out the 
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possibility that PRMT5 might directly regulate 
these genes. 
 
Discussion 
We showed in this study that high fat 
diet induced obese mice have increased levels of 
PRMT5 in the liver but not in other 
metabolically active organs such as adipose 
tissues and muscle. We found that this elevated 
hepatic PRMT5 is associated with high fat diet 
rather than obesity per se.  It has been shown 
that HFD dramatically changed chromatin 
structure, transcription factor binding  and  the 
gene expression landscape in mouse liver.  
Many genes associated with lipid, steroid, 
cholesterol and amino acid metabolism, 
gluconeogenesis, inflammatory response, 
oxidative stress and oxidoreductase activity were 
altered. It is not clear whether the up-regulation 
of PRMT5 is one of the early events which 
further shapes the chromatin environment and 
impacts gene expression under HFD or if it is 
regulated by other key transcription factors 
involved in this process.   
PI3K/AKT signaling plays a critical role 
in regulating diverse cellular functions including 
metabolism, growth, proliferation, cell survival, 
transcriptional activity and protein 
synthesis. Dysregulation of the PI3K/AKT 
pathway is implicated in cancer, type 2 diabetes, 
insulin resistance, inflammatory and 
autoimmune disorders, cardiovascular and 
neurological diseases (12). The comprehensive 
understanding of AKT signaling network has 
been expanded with the identification of 
numerous downstream pathways (54-56). In 
contrast, our knowledge of the upstream 
regulator or activtor of AKT is limited. Wei et al 
reported that overexpressing GFP-PRMT5 led to 
an increase in phospho-AKT levels in 293T cells 
(30). However,  this observation was not further 
validated with the  endogenous protein (30). In 
this study, we identified endogenous PRMT5, an 
epigenetic modifier, as the upstream regulator of 
AKT activation in the context of high fat diet-
induced fatty liver. Wei and co-workers also 
showed that overexpressing GFP-PRMT5 
increased mTOR S2448 phosphorylation, which 
might be the mechanism by which PRMT5 
regulates phospho-AKT (30). We did not detect 
any change in phospho-mTOR S2448 levels in 
PRMT5 knockout MEF cells nor in AML12 
cells with PRM5 knockdown or treated with 
EPZ015666 (Supplemental Figure 2, 3 and 5 ). 
In the present study, PRMT5 regulation of 
phospho-AKT appears to be independent of 
mTOR signaling. AKT activation involves the 
phosphorylation of two residues, Thr308 in the 
activation loop and Ser473 in the C-terminal 
hydrophobic motif. Phosphorylation of Ser473 
has been extensively studied in cancers as a 
marker for full AKT activity (57-59).  Other 
studies also showed that Thr308 is 
predominantly phosphorylated in activated AKT 
kinase in tumor cells (60-62). In our study, 
knockdown of PRMT5 or treatment with 
PRMT5 enzymatic inhibitor EPZ015666 in 
hepatocytes attenuated both phospho-AKT 
Thr308 and Ser473. Our results indicate that 
targeting PRMT5 blocks the activation of AKT, 
which may have a profound effect on its 
downstream signaling networks.  
Mitochondrial dysfunction is associated 
with many diseases, such as type 2 diabetes and 
neurodegenerative diseases (63,64). PGC-1α is 
a master regulator of mitochondrial biogenesis 
by activating transcription factors nuclear 
respiratory factor 1 and nuclear respiratory 
factor 2. These induce mitochondrial 
transcription factor A which drives the 
transcription and replication of mitochondrial 
DNA (64,65). PGC-1α expression levels are 
regulated in response to a plethora of stimuli, 
such as exercise, feeding, fasting, and cold 
exposure and modulated by numerous factors, 
such as Ca2+/calmodulin-dependent protein 
kinase IV (CaMKIV) and calcineurin A, AMP-
activated protein kinase (AMPK) and p38 
mitogen-activated protein kinase (p38 MAPK) 
(66,67). We herein report that PRMT5 repressed 
the expression of PGC-1α in hepatocytes. 
Silencing or complete loss of PRMT5 increased 
the expression of PGC-1α and mitochondrial 
biogenesis. AKT was found to phosphorylate 
and inhibit  PGC-1α (68). PRMT5 ChIP-seq in 
MDA-MB-231 cells did not identify PRMT5 
binding sites at the gene loci of PPARα and 
PGC-1α (50). With no PRMT5 ChIP-seq data 
from hepatocytes, we cannot completely dismiss 
the possibility that PRMT5 might have a direct 
role in regulating these genes. Introducing 
activated Myr-AKT to PRMT5 knockout MEF 
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or knockdown AML12 cells decreased the up-
regulation PPAR α  and PGC-1α. These results 
suggest that it is more likely that PRMT5 
regulates the expression of PPAR α  and PGC-
1α via AKT signaling.  
The overexpression of PRMT5  in 
various cancers has been linked to cancer 
progression and poor prognosis (34,69). 
Therefore, PRMT5 is well recognized as a 
viable therapeutic target in cancer treatment and 
a number of inhibitors have been developed 
within the past couple of years to target cancer, 
β-thalassemia, or sickle cell 
anemia. EPZ015666 is a potent PRMT5 
inhibitor that has been shown to be active in vivo 
(47). A first time in human, open-label, dose 
escalation study of GSK3326595, a potent and 
selective PRMT5 inhibitor similar to 
EPZ015666, in subjects with advanced or 
recurrent solid tumors, as well as subjects with a 
subset of solid tumors and non-Hodgkin's 
lymphoma was approved by the FDA and started 
in August 2016 (ClinicalTrials.gov Identifier: 
NCT02783300). We now report that inhibiting 
PRMT5 by EPZ015666 markedly decreased 
both phospho-AKT Thr308 and phospho-AKT 
Ser473, up-regulated PPARα and PGC-1α 
expression and significantly increased 
mitochondrial biogenesis. Excessive intake of 
dietary lipids was shown to decrease hepatic 
PPARα and PGC-1α expression with a reduced 
number in the numerical density of hepatic 
mitochondria (70). A number of PPARα 
agonists have been shown to enhance hepatic 
mitochondrial biogenesis and increase fatty acid 
β-oxidation in diet-induced obese mice (71,72). 
As an upstream regulator of AKT, PPARα and 
PGC-1α, PRMT5 might be a valuable target to 
treat fatty liver via multiple mechanisms, or 
even more broadly applied to other diseases that 
are associated with mitochondrial dysfunction.  
Chen et al reported that PRMT5 methylates 
GATA 4 and inhibits its transcriptional activity 
in cardiomyocytes which is important in 
prevention of cardiac hypertrophy and heart 
failure (73).  Thus the balance of PRMT5 levels 
in the context of different diseases needs to be 
considered in developing PRMT5 inhibition 
based therapies. 
 
Experimental procedures 
Animals  
C57BL/6 (BL6) mice were housed in a 
temperature-controlled environment with a 12-
hour light, 12-hour dark cycle and fed a standard 
chow ad libitum. Starting at 8 weeks of age, 
male mice were fed ad libitum either a regular 
diet (RD; 12% fat content) or a high fat diet (HF; 
45% fat content, catalog no. D12451; Research 
Diets, New Brunswick, NJ) for 3 months (74). 
Animals were then euthanized and tissue 
samples were collected to be either snap frozen 
in liquid nitrogen or embedded in OCT blocks. 
The Agouti mice were housed in a temperature-
controlled environment with a 12-hour light, 12-
hour dark cycle and fed a standard chow ad 
libitum. All procedures were approved by the 
Institutional Animal Care and Utilization 
Committee (IACUC) at the University of Toledo. 
 
Cell culture 
Nontransformed alpha mouse liver 12 
(AML12) cell line was provided by Dr. Anthony 
Imbalzano (UMass Medical School). This cell 
line was established from hepatocytes from a 
mouse (CD1 strain, line MT42) transgenic for 
human TGF alpha(75).  AML12 cells retain the 
capacity to express high levels of serum and 
liver specific proteins(75). These cells were 
maintained in monolayers, as described (75). 
They were cultured in DMEM/F12 medium 
(Invitrogen, San Diego, CA, USA) 
supplemented with 10% fetal bovine serum 
(FBS) (Sigma-Aldrich, St. Louis, MO), 100 
μg/ml streptomysin, and ITS (Invitrogen). 
HEK293T cells were cultured in DMEM 
medium (Invitrogen) with 10% FBS and 100 
μg/ml streptomysin. PRMT5flox/flox MEFs were 
immortalized with PRMT5flox/flox mouse embryo 
fibroblasts and obtained from Dr. Mark Bedford 
(at the The University of Texas MD Anderson 
Cancer Center). 
 
Lentiviral shRNA construction and 
transduction 
PRMT5 shRNA knockdown lentiviral 
constructs were prepared using psp-108 vector 
(Addgene), and the lentivirus cDNAs were 
produced by co-transfecting with plasmids 
pMD2.G (Addgene) and psPAX2 (Addgene) 
into HEK293T cells. Titers were determined and 
the same number of virus was used, as indicated. 
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PRMT5 knockdown targeting sequences are: 
shRNA15’GCACAGTTTGAGATGCCTTAT3’; 
shRNA2 5’CCTCTTGTGAATGCGTCTCTT3’. 
The Flag-PRMT5 and Flag-PRMT5 PRMT5 
(G367A, R368A) double mutant were from Dr. 
Said Sif (at Qatar University) (46). 
 
Transcient Transfection 
              Cells were plated in 6-well plates or 60 
mm dishes to 60-70% confluency, then 
transfected with 6 or 15 µg plasmid DNA 
respectively using Lipofectamine 2000 
transfection reagent following the 
manufacturer’s protocol. Cells were harvested 
48 hours post transfection for protein analysis by 
western blotting. 
 
Immunofluorescence 
Cells were seeded on glass cover slips 
and incubated overnight. For mitochondria 
staining, cells were incubated with 
MitotrackerTM Red CMXRos (250nM, 
ThermoFisher, cat#M7512) at 37oC for 30 min, 
before being fixed with 4% paraformaldehyde 
for 20 min at room temperature, followed by 
permeabilization in ice-cold methanol for 10 
min at –20°C. Cells were then incubated in 
blocking buffer (5% bovine serum albumin in 
PBS) for 1h at room temperature followed by 
incubation with anti-PRMT5 antibody (Santa 
Cruz Biotechnology, cat# sc-376937) and anti-β-
tubulin antibody (Cell Signaling Technology, 
cat# 15115) at 4°C overnight. Cells were washed 
three times for 5 min in PBS, and then incubated 
for 2h with Alexa Fluor 488-conjugated goat 
anti-mouse secondary antibody against PRMT5 
and Alexa Fluor 555-conjugated goat anti-rabbit 
secondary antibody for β-tubulin (diluted 1:100 
in blocking buffer; Invitrogen) at room 
temperature. Finally, the nuclei were stained 
with DAPI for 30 min at room temperature 
before visualization.  
Formalin-fixed and paraffin-embedded 
tissue sections were deparaffinized and 
rehydrated through graded ethanol solutions. 
The slides were incubated with blocking buffer 
(PBS containing 5% normal goat serum and 0.3% 
Triton X-100) for 60 min and then the slides 
were incubated with PRMT5 antibody at 4°C 
overnight. Subsequently, the slides were washed 
with PBS, and incubated with Alexa Fluor 488-
conjugated goat anti-mouse secondary antibody 
and DAPI for 2h before observation using Leica 
fluorescent microscope. 
 
Real time quantitative RT-qPCR 
Total RNA was extracted from AML12 
cells or MEF cells using Trizol regent 
(Invitrogen) and cDNA was synthesized by 
SuperScript Reverse Transcriptase III kit 
(Invitrogen) according to the manufacturer's 
instruction. The cDNA was amplified in 96-well 
reaction plates with a SYBR green PCR Master 
Mix (Applied Biosystems) on an ABI 7500 real-
time PCR thermocycler. The sequences of 
forward and reverse primers are listed in 
Supplementary Table 1. The relative level of 
target transcripts were calculated from duplicate 
samples after normalization against U36 
housekeeping gene. Dissociation curve analysis 
was performed after PCR amplification to 
confirm primers’ specificity. Relative mRNA 
expression was calculated using the ΔΔCT 
method. 
 
Western blot analysis  
Tissue or cells were washed with cold 
PBS and lyzed in 1% NP40 lysis buffer 
containing a protease and phosphatase inhibitor 
cocktail (Roche Diagnostics, Indianapolis, IN, 
USA). Proteins were analyzed by SDS-PAGE 
followed by immunoprobing with the following 
antibodies: PPARα: sc-398394; PRMT5: sc-
376937; ACCα: sc-137104; FASN: sc-48357; 
SREBP1: sc-365513; mTOR: sc-293089; p-
mTOR: sc-293133.  For normalization, 
monoclonal antibodies against β-tubulin 
(DSHB#E7-S) was used. Blots were incubated 
with horseradish peroxidase-conjugated anti-
goat IgG (Santa Cruz Biotechnology), anti-
mouse or anti-rabbit IgG (GE Healthcare Life 
Science, Pittsburgh, PA, USA) antibodies, and 
proteins detected by enhanced 
chemiluminescence (ECL; GE Healthcare Life 
Science).  
 
Fatty acid Treatments  
Cells were pretreated with increasing 
doses of EPZ015666 for 6 days and seeded at   
density 10,000 cells/well in 24-well plates and 
cultured for 24 hours. Palmitic acid (PA) 
(Sigma-Aldrich, cat#P0500) and oleic acid (OA) 
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(Sigma-Aldrich, cat#O1008) were prepared by 
conjugation with non-fat bovine serum albumin 
(Sigma-Aldrich, cat#A8806). Cells at 50% 
confluency were exposure to 1 µM PA and 100 
µM OA in the presence of EPZ015666 for 5 
days. Lipid droplets were stained with Oil Red O. 
 
Oil Red O staining  
To assess intracellular neutral lipid, FA 
treated cells were fixed using 10% formalin and 
stained using Oil-Red-O (Sigma Aldrich, St. 
Louis, MO) for 30 minutes at room temperature. 
Stained cells were washed with water and rinsed 
with 60% isopropanol. Lipid accumulation were 
visualized using light microscopy. 
 
MTT assay 
              Cell proliferation was measured using 
the MTT assay. Three thousand cells from each 
treated group were plated in a 96-well plate. Cell 
proliferation was measured at 24 hour intervals 
by adding MTT solution (final concentration 5 
µg/mL) to each well and incubating for 4 hours. 
After removal of the media, the plate was air-
dried and 100 µL DMSO added. The plate was 
incubated at room temperature for 30 min with 
gentle shaking. Absorbance was measured at 
OD540 in a Synergy H4 Hybrid microplate 
reader (Bio Tek, Winooski, VT). 
 
ActivSignal IPAD assay 
Cells were lysed in PBS + 1%NP40 
lysis buffer, and submitted to ActivSignal for 
further processing (http://www.activsignal.com). 
The expression or protein phosphorylation of 70 
key proteins involved in more than 20 signaling 
pathways was analyzed by antibodies with high 
specificity and sensitivity in combination of two 
distinct antibodies per each target.  The signal 
was normalized to the expression of 
housekeeping genes. Each pathway is covered 
by multiple targets. The experiment was 
performed twice.  
 
KEGG pathway enrichment analysis 
Proteins with more than 1.5 fold change 
after PRMT5 knockdown in IPAD assay were 
fetched to perform pathway enrichment analysis 
using DAVID (76). Pathway annotations from 
KEGG pathway database with a p-value smaller 
than 0.05 were defined as significantly enriched 
(77). 
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Figure legend 
Figure 1. PRMT5 is ubiquitously expressed in mouse tissues. A. PRMT5 protein levels in mouse tissues 
were determined by Western blot analysis. B. Localization of PRMT5 in mouse AML12 liver cell line. 
PRMT5 expression was visualized by immunofluorescent staining (green), cytoskeleton was labeled by 
immunofluorescent staining of tubulin (red) and nuclei were stained by DAPI (blue), size bar: 200 µm.  All 
images represent 3 independent experiments. 
 
Figure 2. High-fat diet increases hepatic PRMT5 expression. PRMT5 protein (A) and mRNA (B) levels in 
mouse livers fed a normal regular chow (RD) or high-fat diet (HFD) were examined by Western blot 
analysis or qRT-PCR. Total protein or RNA was extracted from livers of 4 months-old male mice after 12 
weeks of feeding with RD or HFD, respectively. C. PRMT5 expression in liver sections of above samples 
were analyzed by immunofluorescent staining of PRMT5 (green), and DAPI nuclear staining (blue), size 
bar: 200 µm. D. PRMT5 levels in muscle, brown or white adipose tissues from mice fed on normal diet or 
high fat diet were analyzed by Western blot. E. PRMT5 expression in the livers of lean or obese Agouti 
mice was measured by Western blot. Total protein was extracted from livers of RD-fed 1- or 5 month-old 
Agouti mice. *** p<0.001, two-tailed Student’s t test. 
 
Figure 3. Silencing PRMT5 decreases PI3K/AKT signaling. A. Western blot analysis of PRMT5 in AML12 
cells following lentiviral shRNA knockdown of PRMT5. B. Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathway analysis of differential expressed proteins with PRMT5 knockdown. Total protein 
extracted from scramble or PRMT5 knockdown cells was analyzed for the expression of key proteins 
involved in more than 20 signaling pathways. Signals were normalized to alpha and beta tubulin. Results 
were obtained from 2 independent experiments performed in duplicate. Reduction of phospho-AKT Thr308 
and Ser473 was observed in PRMT5 knockdown liver cells (C) as well as PRMT5 knockout MEF cells (D). 
E. High fat diet up-regulated the hepatic expression of phospho-AKT Thr308 and Ser473. Total protein 
was extracted from livers of 4 month old male mice fed on either normal or high fat diet for 12 weeks. 
 
Figure 4. PRMT5 regulates master transcription factors of fatty acid metabolism and mitochondrial 
biogenesis. A. RT-qPCR analysis of the mRNA levels of PRMT5, PPARα and PGC-1α in AML12 cells 
expressing either a scrambled sequence shRNA or shRNA-PRMT5. B. Western blot analysis of PPARα in 
scramble and shRNA-PRMT5 AML12 cells. C. Western blot analysis of PRMT5 and PPARα in wild-type 
MEF and PRMT5 knockout MEF cells. D. Expression of mitochondrial biosynthesis genes by qRT-PCR 
in scramble or shRNA-PRMT5 cells. E. Relative mRNA expression of mitochondrial biosynthesis genes 
measured by qRT-PCR in wild-type MEF and PRMT5 knockout MEF cells. Mitochondria in PRMT5 flox/flox  
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wild type or knockout MEF (F) and AML12 cells with scramble or PRMT5 knockdown (G) were stained 
by mitochondrion selective dye MitotrackerTM Red CMXRos, PRMT5 expression was visualized by 
immunofluorescent staining (green), and nuclei were labeled by DAPI (blue), size bar: 200 µm. Each bar 
presents the mean of 3 independent experiments performed in triplicates; error bars are standard deviations.  
** p < 0.01, ***p < 0.001, two-tailed Student’s t test. 
 
Figure 5. PRMT5 enzymatic activity is required for its regulation of PPARα expression. A. A flag-tagged 
wild-type or enzyme-dead (G367A, R368A) double PRMT5 mutant was introduced to AML12 wells by 
transient transfection. The expression of exogenous proteins was examined by Western blot analysis using 
anti-flag antibody. The total levels of PRMT5 were measured by Western blot against anti-PRMT5 antibody. 
B. AKT phosphorylation and expression of PPARα in wild type or mutant PRMT expressing cells were 
analyzed by Western blot. C. Protein levels of phospho-AKT and PPARα were determined by Western blot 
in AML12 cells treated with DMSO or increasing doses of the PRMT5 inhibitor EPZ015666. D. The 
relative mRNA of PPARα and PGC-1α was measured by qRT-PCR in AML12 cells treated with DMSO 
or increasing doses of EPZ015666. E. AML12 cells treated with DMSO or 100nM EPZ01666 were stained 
by MitotrackerTM Red CMXRos (red) and nuclei labeled by DAPI (blue), size bar: 200 µm. ***p < 0.001, 
two-tailed Student’s t test. F. AML12 cells pre-treated with DMSO or 100nM EPZ01666 were exposed to 
media containing 1 µM palmitic acid and 100 µM oleic acid for 5 days. Intracellular lipids were stained 
with Oil Red O. 
 
Figure 6. PRMT5 regulates PPARα and PGC-1α expression via AKT signaling. A. PRMT5 flox/flox  wild 
type or knockout MEF cells were transfected with vector or Myr-AKT and harvested 48 hours post-
transfection. Protein samples were analyzed by Western Blot for PPARα and PGC-1α expression. B. 
AML12 cells were transduced with scramble or shPRMT5 viral supernatant for 24 hours then selected in 
media containing 2 µg/mL puromycin for 48 hours. Then cells were transfected with vector or Myr-AKT 
and harvested 48 hours post-transfection. Protein samples were analyzed by Western blot for PPARα and 
PGC-1α expression. 
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